Levetiracetam is a drug used to treat epilepsy. It belongs to a group of drugs called antiepileptics, which work by reducing the number and severity of seizures.
Use & indications
Levetiracetam is used alone (monotherapy), without other anti-epilepsy medications, to treat a certain type of epilepsy (partial seizures that initially affect only one side of the brain) in adults and adolescents 16 years of age and older.
Levetiracetam can also be used as an add-on treatment, meaning it is used in combination with other medications to control seizures that are not well controlled by those other medications alone.
Indications as an add-on treatment include:
- partial seizures with or without secondary generalization in adults, adolescents, children, and infants 1 month of age and older
- myoclonic seizures (brief shock-like twitching of a muscle or muscle group) in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy
- Primary generalized tonic-clonic seizures (pronounced seizures, including loss of consciousness) in adults and adolescents 12 years of age and older with idiopathic generalized epilepsy (a hereditary form of epilepsy)
The dosage of levetiracetam is usually 250, 500, 750, or 1000 mg when taken as film-coated tablets. The dosing interval here is usually 2 intakes per day. Levetiracetam is also available as an oral solution and in the form of concentrates for the preparation of infusion solutions.
Levetiracetam is available by prescription throughout the European Union.
Levetiracetam is a modification (derivative) of the substance piracetam, which was used in the past in the treatment of dementia. Levetiracetam was developed by the Belgian pharmaceutical company UCB S.A and patented in 1985.